BOUNDLESS BIO, INC.
Income Statement
| Line Item | FY2026 | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| Revenue | — | — | — | — |
| Cost of Revenue | — | — | — | — |
| Gross Profit | — | — | — | — |
| Gross Margin | — | — | — | — |
| Operating Expenses | ||||
| Research & Development | — | $44.8M | $55.3M | $42.6M |
| SG&A Expense | — | $18.7M | $18.0M | $12.2M |
| Operating Income | — | $-63.6M | $-73.3M | $-54.8M |
| Operating Margin | — | — | — | — |
| Interest Expense | — | — | — | — |
| Pretax Income | — | — | — | — |
| Income Tax Expense | — | $0 | $0 | — |
| Net Income | — | $-58.2M | $-65.4M | $-49.4M |
| Net Margin | — | — | — | — |
| EPS (Basic) | — | $-2.60 | $-3.85 | $-2.90 |
| EPS (Diluted) | — | $-2.60 | $-3.85 | $-2.90 |
| Shares Outstanding (Basic) | 22.4M | 22.4M | 17.0M | 17.0M |
| Shares Outstanding (Diluted) | 22.4M | 22.4M | 17.0M | 17.0M |
| Dividends Per Share | — | — | — | — |